Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares of the company's stock, valued at $894,218.78. This trade represents a 15.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Harith Rajagopalan also recently made the following trade(s):

GUTS stock traded down $0.14 during trading on Monday, reaching $1.70. 583,333 shares of the stock were exchanged, compared to its average volume of 409,278. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $81.77 million and a price-to-earnings ratio of -0.14. The business has a 50 day moving average price of $2.06 and a 200-day moving average price of $2.51. Fractyl Health, Inc. has a 1 year low of $1.68 and a 1 year high of $13.99.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. On average, research analysts predict that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA grew its holdings in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company's stock worth $2,646,000 after buying an additional 49,289 shares in the last quarter. Geode Capital Management LLC increased its stake in Fractyl Health by 166.5% in the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company's stock valued at $1,269,000 after purchasing an additional 313,335 shares during the last quarter. State Street Corp boosted its stake in Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company's stock worth $287,000 after buying an additional 63,968 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Fractyl Health by 56.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock valued at $204,000 after buying an additional 29,262 shares during the period. Finally, Barclays PLC increased its stake in shares of Fractyl Health by 1,754.7% during the 3rd quarter. Barclays PLC now owns 47,796 shares of the company's stock valued at $121,000 after acquiring an additional 45,219 shares during the last quarter.

Separately, Morgan Stanley reduced their target price on Fractyl Health from $18.00 to $10.00 and set an "overweight" rating for the company in a report on Monday.

View Our Latest Research Report on Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Fractyl Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.

While Fractyl Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.